(BMY) Bristol-Myers Squibb - Overview
Sector: Healthcare | Industry: Drug Manufacturers - General | Exchange: NYSE (USA) | Market Cap: 121.422m USD | Total Return: 32.8% in 12m
Avg Turnover: 544M
EPS Trend: 13.4%
Qual. Beats: 0
Rev. Trend: 92.2%
Qual. Beats: 10
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical firm focused on the discovery and commercialization of therapies across oncology, hematology, immunology, cardiovascular, and neuroscience sectors. Its portfolio includes high-revenue assets such as Opdivo for cancer treatment, Eliquis for stroke prevention, and Revlimid for multiple myeloma. The company operates through a research-intensive business model, utilizing patent protection to maintain market exclusivity on proprietary molecular entities before facing generic competition.
The pharmaceutical industry is characterized by high capital expenditures and long regulatory lead times, with success often dependent on the strength of a companys late-stage clinical pipeline. BMY distributes its products primarily through wholesalers, specialty pharmacies, and government agencies, maintaining a global supply chain to service both chronic and acute medical conditions. Investors can further explore the fundamental valuation of this company on ValueRay.
Headquartered in Princeton, New Jersey, the firm has evolved from its 1887 origins into a diversified developer of both traditional small-molecule drugs and advanced biologics. Recent expansions into subcutaneous inhibitors and cell therapies like Breyanzi reflect a strategic shift toward specialized, high-margin therapeutic areas designed to offset upcoming patent expirations on legacy products.
- Generic erosion of Revlimid and Eliquis revenue pressures long-term cash flows
- Pipeline execution of newer launches like Camzyos and Sotyktu offsets patent cliffs
- Regulatory pricing pressure from Medicare drug negotiations impacts core cardiovascular portfolio
- High R&D spending on oncology and immunology determines future earnings growth
- Strategic acquisitions and partnership deals influence balance sheet and dividend stability
| Net Income: 7.28b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA -0.39 > 1.0 |
| NWC/Revenue: 16.60% < 20% (prev 14.09%; Δ 2.51% < -1%) |
| CFO/TA 0.15 > 3% & CFO 13.3b > Net Income 7.28b |
| Net Debt (35.9b) to EBITDA (13.8b): 2.61 < 3 |
| Current Ratio: 1.42 > 1.5 & < 3 |
| Outstanding Shares: last quarter (2.04b) vs 12m ago 0.32% < -2% |
| Gross Margin: 68.75% > 18% (prev 0.59%; Δ 6.82k% > 0.5%) |
| Asset Turnover: 54.20% > 50% (prev 51.54%; Δ 2.66% > 0%) |
| Interest Coverage Ratio: 7.35 > 6 (EBITDA TTM 13.8b / Interest Expense TTM 1.43b) |
| A: 0.09 (Total Current Assets 27.2b - Total Current Liabilities 19.2b) / Total Assets 86.5b |
| B: 0.21 (Retained Earnings 18.3b / Total Assets 86.5b) |
| C: 0.12 (EBIT TTM 10.5b / Avg Total Assets 89.5b) |
| D: 0.26 (Book Value of Equity 17.2b / Total Liabilities 66.4b) |
| Altman-Z'' = 2.36 = BBB |
| DSRI: 0.63 (Receivables 9.37b/14.6b, Revenue 48.5b/47.6b) |
| GMI: 0.86 (GM 68.75% / 59.16%) |
| AQI: 1.04 (AQ_t 0.60 / AQ_t-1 0.58) |
| SGI: 1.02 (Revenue 48.5b / 47.6b) |
| TATA: -0.07 (NI 7.28b - CFO 13.3b) / TA 86.5b) |
| Beneish M = -3.49 (Cap -4..+1) = AA |
As of May 23, 2026, the stock is trading at USD 59.46 with a total of 6,488,240 shares traded.
Over the past week, the price has changed by +4.32%,
over one month by +1.12%,
over three months by -1.92% and
over the past year by +32.75%.
Bristol-Myers Squibb has received a consensus analysts rating of 3.48. Therefore, it is recommended to hold BMY.
- StrongBuy: 6
- Buy: 4
- Hold: 18
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 63 | 5.9% |
P/E Forward = 9.434
P/S = 2.5045
P/B = 6.0597
P/EG = 188.748
Revenue TTM = 48.5b USD
EBIT TTM = 10.5b USD
EBITDA TTM = 13.8b USD
Long Term Debt = 42.2b USD (from longTermDebt, last quarter)
Short Term Debt = 2.31b USD (from shortTermDebt, last quarter)
Debt = 46.4b USD (from shortLongTermDebtTotal, last quarter) + Leases 1.97b
Net Debt = 35.9b USD (calculated: Debt 46.4b - CCE 10.5b)
Enterprise Value = 157b USD (121b + Debt 46.4b - CCE 10.5b)
Interest Coverage Ratio = 7.35 (Ebit TTM 10.5b / Interest Expense TTM 1.43b)
EV/FCF = 13.22x (Enterprise Value 157b / FCF TTM 11.9b)
FCF Yield = 7.57% (FCF TTM 11.9b / Enterprise Value 157b)
FCF Margin = 24.56% (FCF TTM 11.9b / Revenue TTM 48.5b)
Net Margin = 15.01% (Net Income TTM 7.28b / Revenue TTM 48.5b)
Gross Margin = 68.75% ((Revenue TTM 48.5b - Cost of Revenue TTM 15.2b) / Revenue TTM)
Gross Margin QoQ = 70.22% (prev 67.23%)
Tobins Q-Ratio = 1.82 (Enterprise Value 157b / Total Assets 86.5b)
Interest Expense / Debt = 3.07% (Interest Expense 1.43b / Debt 46.4b)
Taxrate = 17.31% (561.0m / 3.24b)
NOPAT = 8.67b (EBIT 10.5b * (1 - 17.31%))
Current Ratio = 1.42 (Total Current Assets 27.2b / Total Current Liabilities 19.2b)
Debt / Equity = 2.31 (Debt 46.4b / totalStockholderEquity, last quarter 20.1b)
Debt / EBITDA = 2.61 (Net Debt 35.9b / EBITDA 13.8b)
Debt / FCF = 3.02 (Net Debt 35.9b / FCF TTM 11.9b)
Total Stockholder Equity = 18.6b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.13% (Net Income 7.28b / Total Assets 86.5b)
RoE = 39.05% (Net Income TTM 7.28b / Total Stockholder Equity 18.6b)
RoCE = 17.26% (EBIT 10.5b / Capital Employed (Equity 18.6b + L.T.Debt 42.2b))
RoIC = 13.75% (NOPAT 8.67b / Invested Capital 63.1b)
WACC = 5.64% (E(121b)/V(168b) * Re(6.83%) + D(46.4b)/V(168b) * Rd(3.07%) * (1-Tc(0.17)))
Discount Rate = 6.83% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 80.90 | Cagr: 0.23%
[DCF] Terminal Value 74.12% ; FCFF base≈12.4b ; Y1≈11.5b ; Y5≈10.4b
[DCF] Fair Price = 63.03 (EV 165b - Net Debt 35.9b = Equity 129b / Shares 2.04b; r=8.35% [WACC [floored]]; 5y FCF grow -9.00% → 2.50% )
EPS Correlation: 13.41 | EPS CAGR: 14.52% | SUE: 0.46 | # QB: 0
Revenue Correlation: 92.21 | Revenue CAGR: 3.10% | SUE: 2.58 | # QB: 10
EPS current Quarter (2026-06-30): EPS=1.61 | Chg30d=-2.01% | Revisions=-20% | Analysts=22
EPS next Quarter (2026-09-30): EPS=1.61 | Chg30d=-1.18% | Revisions=-50% | Analysts=22
EPS current Year (2026-12-31): EPS=6.31 | Chg30d=+0.76% | Revisions=+33% | GrowthEPS=+2.6% | GrowthRev=-1.9%
EPS next Year (2027-12-31): EPS=6.17 | Chg30d=+0.76% | Revisions=+0% | GrowthEPS=-2.2% | GrowthRev=-2.3%
[Analyst] Revisions Ratio: -50%